Is Amorfix withholding relevant investor informatiDo get the feeling Amorfix, is not telling Investors as much as they should be ?
If we look back over the last year.......
ALZHEIMER'S TEST
In 2010, the company reported in their letter from the CEO, that all feasibility studies on Alzheimer's should be completed by the end of 2010 moving us into the validation stage of human clinical samples.
January 7, 2011: Press Release announces preliminary results indicating that their human Alzheimer's (AD) diagnostic assay can detect a signal from aggregated beta amyloid in the spinal fluid (CSF) from AD patients.
January 11, 2011: Corporate Update in San Francisco- if you refer to events under Investor Relations on the Amorfix page, launch the webcast and listen to the audio as to the words Dr. Gundel said ! " We are now in the process of continuing to analyze a large number of clinical samples to continue to develop and optimize the assay conditions. " Further on in the presentation next steps for "Human Alzheimer's Disease Diagnostic " Dr. Gundel's audio commented that "we will continue to optimize the assay by doing analysis on clinical CSF samples and then eventually shift over into working with human blood, and we should complete the evaluation of CSF samples within the next few months."
CANCER ANTIBODIES
- In May and June of 2010 Amorfix signs agreements with Epitomics, Aragen and QED Bioscience tot develop high affinity monoclonal against a number of targets for cancer. In talking with cmpy officials last summer it generally takes 3-7 months to produce these antibodies. On November 23,2010- Amorfix announces together with Epitomics that they have produced high affinity antibodies to prion protein PrP (DSE's). We are now in the process of fully characterizing the binding properties and biological activity of these antibodies. " We expect to initiate our animal proof of concept studies in the first calendar quarter of next year."
- Early December 2010 - CEO letter comments we expect to initiate our cancer animal model proof of concept studies in the " second calendar quarter of 2011."
- On January 11, 2011- At its' Corporate Update in San Francisco the Company under Cancer Therapeutics reports that animal model proof of concept studies scheduled for early " Q2 2011."
- February 14, 2011 - Press Release - The company expects to initiate animal model proof of concept studies for the PrP antibodies in the " second quarter of this year. "
-August 11, 2011- The company announces that it has completed the initial characterization of it's PrP Antibodies Assay Systems. The company will be preparing to advance the program into proof of concept studies in animal models of cancer.
Recapping: In November, 2010 the company reported they had developed antibodies with Epitomics and expected to be conducting animal proof of concept studies first calendar quarter of 2011. Not sure 15 months later why Amorfix is just finishing fully characterizing the binding properties and biological activities of these antibodies? I saw on the Epitomics web page their SVC timeline for developing custom antibodies is 6-7 months. This is what we were told last summer and as an example what happened with The National Cancer Institute (NCI) of the U.S. December 15, 2010 Epitomics signs with (NCI) of the U.S., July 26, 2011 Epitomics releases new antibodies developed with the National Cancer Institute for sale through their distributors. I contacted Epitomics and asked them when they develop custom antibodies for their clients, does this mean fully characterizing the binding properties and biological activities of these antibodies ? Epitomics replied back in an e-mail " Yes, the hydridomas delivered to you will be full characterized by ELISA ( at Epitomics.)" Not quite sure what Amorfix is doing ?